CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading compound profile…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Cannabinoids/2-Arachidonoylglycerol

Endocannabinoids

2-Arachidonoylglycerol

An endocannabinoid and an endogenous agonist of the cannabinoid receptors (CB1 and CB2). It is an ester formed from omega-6-arachidonic acid and glycerol.

Definition: CHEBI:52392 · Chemical Entities of Biological Interest · release 253

1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol2-AG2-arachidonoyl glycerol2-Arachidonoyl-glycerol2-ARACHIDONOYLGLYCEROL2-Arachidonyl-glycerol2-Arachidonylglycerol2-Ara-Gl

531public articles

14registered condition areas

All documents →

Identity & provenance

Chemical identity

C23H38O4 · molecular weight 378.553

CAS: cas:53847-30-6↗CHEBI: CHEBI:34261↗CHEBI: CHEBI:52365↗CHEBI: CHEBI:52392↗GSRS_UUID: 701ab37d-c9c3-4f61-8182-50b3aa92369f↗HMDB: hmdb:HMDB0004666↗INCHI: InChI=1S/C23H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)27-22(20-24)21-25/h6-7,9-10,12-13,15-16,22,24-25H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-↗INCHIKEY: RCRCTBLIHCHWDZ-DOFZRALJSA-N↗KEGG.COMPOUND: kegg.compound:C13856↗LIPIDMAPS: lipidmaps:LMGL01010023↗METACYC.COMPOUND: metacyc.compound:CPD-12600↗PUBCHEM_CID: 5282280↗PUBMED: pubmed:12878451↗PUBMED: pubmed:15543349↗PUBMED: pubmed:18771906↗REAXYS: reaxys:8167264↗UNII: 8D239QDW64↗WIKIPEDIA.EN: wikipedia.en:2-Arachidonoylglycerol↗

Sources: ChEBI · 253 FDA GSRS / UNII · 8 PubChem computed properties · pug-bcca51ccb147c1e4

0 referenced plant-occurrence records. They are identity candidates, not clinical evidence.

Research areas

Conditions found alongside this compound

Document links and organism occurrence are candidates, not proof of efficacy, safety or a treatment recommendation.

Epilepsy and cannabinoids

14 matching public articles

Candidate association · not a treatment claim

Chronic pain and cannabinoids

20 matching public articles

Candidate association · not a treatment claim

Multiple sclerosis and cannabinoids

14 matching public articles

Candidate association · not a treatment claim

Parkinson disease and cannabinoids

6 matching public articles

Candidate association · not a treatment claim

Alzheimer disease and cannabinoids

11 matching public articles

Candidate association · not a treatment claim

Anxiety disorders and cannabinoids

4 matching public articles

Candidate association · not a treatment claim

Cancer pain and cannabinoids

2 matching public articles

Candidate association · not a treatment claim

Post-traumatic stress disorder and cannabinoids

14 matching public articles

Candidate association · not a treatment claim

Migraine disorders and cannabinoids

11 matching public articles

Candidate association · not a treatment claim

Inflammatory bowel diseases and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

Opioid-related disorders and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

Linked local records

Medicines and registered studies

Links use source-reported active ingredients or study intervention names and remain candidates, not treatment claims.

Medicines with this active ingredient

No public medicine record matched.

Registered studies

0 exact source-intervention matches.

No registered study intervention matched.

Latest documents

Recent research

2026

A Minimally Invasive LC-MS/MS Approach for Assessing Endocannabinoids in Saliva and Capillary Blood Microsamples.

Biosensors · Free full text

2026

Direct modulation of human GABA-A α1β2γ2 receptors by the endocannabinoid 2-arachidonoylglycerol: implications for cannabinoid-related ligands and limitations for anxiolytic drug development.

Frontiers in Neuroscience · Free full text

2026

Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies.

Cells · Free full text

2026

Exploring cannabinoid receptor CB1 autophagy and the obesity phenotype of p62-deficient mice.

Biochemistry and Biophysics Reports · Free full text

2026

Endocannabinoid modulation of defensive state transitions to innate and learned threat.

Psychopharmacology · Free full text

2026

Relationships among peri-traumatic circulating endocannabinoids and long-term, negative outcomes following traumatic injury.

Psychopharmacology · Free full text

2026

Exercise-induced anandamide–CB1R signaling and prefrontal–amygdala stress circuits in adolescent depression: a critical hypothesis-driven narrative review

Frontiers in Psychiatry · Free full text

Ontology definitions normalize terms; they do not establish medical claims.

Alcohol use disorders and cannabinoids

4 matching public articles

Candidate association · not a treatment claim

Depressive disorders and cannabinoids

10 matching public articles

Candidate association · not a treatment claim

Bipolar disorder and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

2026

Effects of acute alcohol administration on endocannabinoids and relation to subjective effects.

Psychopharmacology · Free full text

2026

Bridging reward and resilience: the endocannabinoid system as a unifying mechanism in exercise-induced protection against major depressive disorder.

Frontiers in Psychiatry · Free full text

2026

Endocannabinoid response to social stress in chronic non-medical prescription opioid users.

Psychopharmacology · Free full text

2026

Temporal multi-omic exploration of the ventral tegmental area in chronic pain and passive coping behaviors.

iScience · Free full text

2026

Associations of cardiorespiratory fitness and muscular fitness with plasma levels of endocannabinoids and their analogues in adults with diagnosed depression: SONRIE study.

European Archives of Psychiatry and Clinical Neuroscience · Free full text